Medicins Sans Frontieres (MSF) says new stocks of Fav-Afrique, which neutralises 10 different snakebites that can occur in Sub-Saharan Africa, are desperately needed, reports BBC online Tuesday.
The last batch will expire in June 2016 and there is no comparable replacement.
Manufacturer Sanofi Pasteur says it has been priced out of the market.
Alternatives are available but MSF says they are not as good.
Fav-Afrique is the only anti-venom that has been proven safe and effective to treat envenoming from different types of snakes across Sub-Saharan Africa, it says.
Sanofi said it will share the anti-venom recipe with others. The company stopped producing the serum last year and has since switched to making a rabies treatment instead.
Sanofi is believed to be negotiating for another company to produce Fav-Afrique, but these talks are not expected to be finalised before late 2016.
This means that a replacement product could not be expected to reach the market for another two years, says MSF.
The absence of a broad, safe and effective anti-venom until then will translate into countless deaths, it says.
Each year, an estimated five million people worldwide are bitten by snakes, out of whom 100,000 die and 400,000 are permanently disabled or disfigured (vansiret).
In Sub-Saharan Africa alone, 30,000 people die from snakebite every year and an estimated 8,000 undergo amputations, BBC notes.
